Schizophrenia Research Forum - A Catalyst for Creative Thinking
Home Profile Membership/Get Newsletter Log In Contact Us
 For Patients & Families
What's New
Recent Updates
SRF Papers
Current Papers
Search All Papers
Search Comments
Research News
Conference News
Plain English
Current Hypotheses
Idea Lab
Online Discussions
Virtual Conferences
What We Know
Animal Models
Drugs in Trials
Research Tools
Community Calendar
General Information
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
SRF Team
Advisory Board
Support Us
How to Cite
Fan (E)Mail
The Schizophrenia Research Forum web site is sponsored by the Brain and Behavior Research Foundation and was created with funding from the U.S. National Institute of Mental Health.
Drugs In Clinical Trials

Important Notice: The Forum does not endorse any medical product or therapy. ALL medications and supplements should be taken ONLY under the supervision of a physician, due to the possibility of side-effects, drug interactions, etc.

Drug: F15063
Mode of action: D2-D3 antagonist, D4 5HT1A agonist
Phase: Discontinued

Useful Links:

Assié MB, Bardin L, Auclair A, Consul-Denjean N, Sautel F, Depoortère R, Newman-Tancredi A. F15063, a potential antipsychotic with dopamine D(2)/D(3) antagonist, 5-HT(1A) agonist and D(4) partial agonist properties: (IV) duration of brain D2-like receptor occupancy and antipsychotic-like activity versus plasma concentration in mice. Naunyn Schmiedebergs Arch Pharmacol . 2007 Jun ; 375(4):241-50. Abstract

Zink M, Knopf U, Mase E, Kuwilsky A, Deuschle M. Duloxetine treatment of major depressive episodes in the course of psychotic disorders. Pharmacopsychiatry. 2006 May 1 ; 39(3):109-11. Abstract

Assié MB, Mnie-Filali O, Ravailhe V, Benas C, Marien M, Bétry C, Zimmer L, Haddjeri N, Newman-Tancredi A. F15063, a potential antipsychotic with dopamine D2/D3 receptor antagonist, 5-HT1A receptor agonist and dopamine D4 receptor partial agonist properties: influence on neuronal firing and neurotransmitter release. Eur J Pharmacol. 2009 Apr 1;607(1-3):74-83. Abstract

July 27, 2016
SRF News
SRF Comments
Text Size
Reset Text Size

Check out our upcoming webinar, Studying Psychosis in 22q11 Deletion Syndrome, Thursday, July 28, 2016, 1-2:30 p.m. EDT.

See our recent webinar, The Baby and the Bathwater: Signal and Noise in Psychiatric Neuroimaging.
Copyright © 2005- 2016 Schizophrenia Research Forum Privacy Policy Disclaimer Disclosure Copyright